Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between infant and toddler gut microbiota composition and later executive functioning.

Development and psychopathology·2026
Same author

Prenatal and Postnatal Maternal Psychological Distress and the Metabolomic Profile of Human Milk.

The Journal of nutrition·2026
Same author

A searchable metadata network graph for microbiome metabolomics.

bioRxiv : the preprint server for biology·2026
Same author

Community Curation of Microbial Metabolites Enables Biological Insights of Metabolomics Data.

bioRxiv : the preprint server for biology·2026
Same author

Prenatal exposure to persistent organic pollutants modulates the metabolism and gut microbiota of the offspring.

Environment international·2026
Same author

A resource to empirically establish drug exposure records directly from untargeted metabolomics data.

Nature communications·2025

Related Experiment Video

Updated: Jul 1, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K

Tetrandrine for Targeting Therapy Resistance in Cancer.

Ellen Nogueira Lima1,2,3, Santosh Lamichhane1,2,3, K C Pramod Bahadur1,3

  • 1Departments of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, LA, USA.

Current Topics in Medicinal Chemistry
|March 6, 2024
PubMed
Summary

Tetrandrine shows promise as an anti-cancer agent that may help overcome therapy resistance. This natural compound could be a valuable addition to existing cancer treatments, improving patient outcomes.

Keywords:
CancerDrug resistanceMDR/ ABCB1 transporterNano-therapeutics.TetrandrineTrail

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

Related Experiment Videos

Last Updated: Jul 1, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Biology

Background:

  • Cancer remains a leading global cause of death despite advances in treatment.
  • Therapy resistance is a major challenge, leading to most cancer-related mortality.
  • Novel therapeutic strategies are urgently needed to combat cancer resistance.

Purpose of the Study:

  • To review mechanisms of cancer therapy resistance.
  • To explore the anti-cancer effects of tetrandrine.
  • To evaluate tetrandrine's potential in overcoming cancer resistance.

Main Methods:

  • Literature review of cancer resistance mechanisms.
  • Review of studies on tetrandrine's anti-cancer properties.
  • Analysis of tetrandrine's potential as an adjuvant therapy.

Main Results:

  • Tetrandrine, a bis-benzyl iso-quinoline, exhibits promising anti-cancer activity.
  • Tetrandrine and its derivatives may serve as effective adjuvants to current cancer drugs.
  • Existing literature supports tetrandrine's role in addressing therapy resistance.

Conclusions:

  • Tetrandrine presents a potential strategy to overcome cancer therapy resistance.
  • Further research into tetrandrine as an adjuvant therapy is warranted.
  • Targeting resistance mechanisms with agents like tetrandrine could improve cancer treatment efficacy.